Table 3.
Differences in baseline characteristics in patients with increased or decreased RDW levels.
| RDW < 13.35% | RDW > 13.35% | p value | |
|---|---|---|---|
| (n = 53) | (n = 81) | ||
| Clinical variables | |||
| Age (years) | 67 (59–71) | 68 (62–74) | 0.08 |
| Male gender | 43 (81) | 67 (82) | 0.81 |
| BMI (kg/m2) | 27 (24–30) | 27 (23–29) | 0.40 |
| Ischemic | 30 (56) | 47 (58) | 0.87 |
| LBBB | 49 (92) | 61 (75) | 0.005 |
| CRT-D | 11 (20) | 11 (13) | 0.27 |
| Opt. lead position | 41 (77) | 57 (70) | 0.37 |
| QRS (msec) | 155 (134–180) | 164 (146–189) | 0.04 |
| LVEF (%) | 28 (24–33) | 25 (23–32) | 0.43 |
| LVESV (mL) | 202 (147–276) | 214 (153–267) | 0.71 |
| LVEDV (mL) | 285 (234–341) | 312 (250–361) | 0.29 |
| NYHA III. IV | 40 (75) | 75 (92) | 0.005 |
| Hypertension | 29 (54) | 45 (55) | 0.92 |
| Hyperlipidemia | 11 (20) | 21 (25) | 0.49 |
| Diabetes m. | 15 (28) | 35 (43) | 0.08 |
| ACEi/ARB | 53 (100) | 75 (92) | 0.04 |
| BB | 49 (92) | 71 (87) | 0.37 |
| MRI | 37 (69) | 57 (70) | 0.94 |
| Laboratory data | |||
| Hematocrit (%) | 43 (39–45) | 41 (37–43) | 0.11 |
| NT-proBNP (pg/mL) | 1817 (691–3086) | 3581 (2007–6232) | <0.0001 |
| Creatinine (μmol/L) | 92 (74–121) | 112 (85–135) | 0.007 |
Data are expressed as medians with interquartile ranges for continuous variables and as event numbers with percentages for categorical variables. For the comparison of continuous data, we used the Mann-Whitney test, whereas the chi squared test was applied for the comparison of the categorical variables. BMI = body mass index; Ischemic = ischemic etiology of the heart failure; LBBB = left bundle branch block; CRT-D = cardiac resynchronization therapy with implantable cardioverter defibrillator; Opt. lead position = lateral or posterolateral position; LVEF = left ventricular ejection fraction; LVESV = left ventricular end systolic volume; LVEDV = left ventricular end diastolic volume; NYHA III, IV = New York Heart Association classification 3-4; ACEi/ARB = angiotensin convertase inhibitor/angiotensin receptor blocker; BB = beta-blocker; MRI = mineralocorticoid receptor inhibitor; NT-proBNP = N-terminal of the prohormone brain natriuretic peptide; RDW = red blood cell distribution width.